SCHEMBL28021745

SCHEMBL28021745

CCCS(=O)(=O)Nc1ccc(S(=O)(=O)c2nc(Nc3cc(C)n[nH]3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.41
PLK4 O00444 3/20 0.41
DAPK3 O43293 3/20 0.41
JAK2 O60674 3/20 0.41
CDK1 P06493 3/20 0.41
RPS6KB1 P23443 3/20 0.41
CDK2 P24941 3/20 0.41
TYK2 P29597 3/20 0.41
CLK2 P49760 3/20 0.41
JAK3 P52333 3/20 0.41
LIMK1 P53667 3/20 0.41
CDK5 Q00535 3/20 0.41
DYRK1A Q13627 3/20 0.41
PKN2 Q16513 3/20 0.41
HIPK4 Q8NE63 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
STK17A Q9UEE5 3/20 0.41
MAP4K2 Q12851 2/20 0.41
AKT3 Q9Y243 2/20 0.41
DYRK3 O43781 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28549341 0.95 ALDH1A1 (0.45) AURKBPLK4DAPK3JAK2CDK1
SCHEMBL28570220 0.86 BPTF (0.38) AURKBALDH1A1HPGDKDM4EMAPT
SCHEMBL28021591 0.85 AURKB (0.51) AURKBALDH1A1HPGDKDM4EMAPT
SCHEMBL28022051 0.85 HRH4 (0.41) AURKBMAPTBPTFTP53SMN1; SMN2
SCHEMBL2203178 0.84 AURKB (0.53) AURKBPLK4DAPK3JAK2CDK1
SCHEMBL28557357 0.84 AURKB (0.49) AURKBALDH1A1HPGDKDM4EMAPT
SCHEMBL28564611 0.82 BPTF (0.42) ALDH1A1HPGDMAPTBPTFTP53
SCHEMBL28548957 0.81 ADORA1 (0.44) AURKBALDH1A1KDM4EMAPTBPTF
SCHEMBL28565368 0.81 AURKB (0.44) AURKBALDH1A1HPGDKDM4EMAPT
SCHEMBL28022116 0.81 ADORA1 (0.47) AURKBALDH1A1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 CN disclosed